PICKERING GRANT sold $901K of PCVX
PICKERING GRANT (CHIEF EXECUTIVE OFFICER) sold 16,198 shares of Vaxcyte, Inc. (PCVX) at an average of $55.63 ($55.52–$55.93, $0.90M total) across 2 trades on 2026-07-27 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest actionable element is the disclosed sale size, price range, and confirmation of a pre-arranged 10b5-1 plan. Without accompanying fundamental updates, the likely effect is sentiment-driven rather than thesis-changing.
Market read
Traders may briefly reassess near-term sentiment around PCVX due to CEO selling, but the 10b5-1 framing reduces interpretive weight.
What to watch
The article does not state whether other insiders sold/bought around the same window, nor does it provide context on total CEO holdings changes beyond the post-transaction share count.
Background
The article is an SEC Form 4 insider transaction disclosure for Vaxcyte, Inc. (PCVX) by its CEO, reported as open-market sales under a Rule 10b5-1 plan.
Ticker impact
Vaxcyte CEO Grant sold 16,198 shares in open-market transactions on 2026-07-27 for about $901,069 under a 10b5-1 plan.
Likely limited, short-lived impact unless accompanied by other company-specific catalysts.
The filing is a primary Form 4 disclosure, but the article provides no new operational, financial, or regulatory developments beyond the sale details and confirms the plan was pre-arranged.
Market effects
Minimal; this is company-specific insider activity with no disclosed sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations, so traders may discount it.
Key entities
- issuerVaxcyte, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderPickering Grant
CEO and director who executed the open-market sales under a 10b5-1 plan.
